RFID meeting
This article was originally published in The Tan Sheet
Executive Summary
A public workshop Feb. 8-9 will allow FDA's Counterfeit Drug Task Force to collect stakeholder input on identifying "incentives for widespread adoption of radio frequency identification (RFID), as well as obstacles," according to a Federal Register announcement Jan. 11. Specifically, the agency seeks input on how to address the likelihood that widespread RFID technology will not be in operation by the current deadline for implementation under the Prescription Drug Marketing Act's pedigree requirements. Comments will "guide the agency's decision whether to continue the delayed effective date, let the regulatory provisions go into effect, or take other steps," the announcement states. In 2004, FDA cited implementation of electronic track and trace capability by 2007 as a priority. However, "it appears that the goals described previously may not be met," FDA states...
You may also be interested in...
No Disguising Need For Enforcement, Education To Curb Counterfeiting
Consumer education programs and increased law enforcement efforts are needed to curtail the counterfeiting of drugs and personal care products, according to a lawyer with a prominent intellectual property law firm
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.